Advanced Filters
noise

Chemotherapy Clinical Trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,512 clinical trials
Z Zhongyu Yuan, Professor

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.

18 - 75 years of age Female Phase 3
F Francesca Magnoni, MD

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC

This study will prospectively determine the feasibility and oncological safety of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NACT) in inflammatory breast cancer patients traditionally considered ineligible for SLNB due to locally advanced cancer with skin/chest wall involvement (cT4d) and heavy nodal burden at presentation (cN1/N2). This study will …

18 years of age Female Phase N/A
J Jin Jie

Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation. In the past decade, with the application of molecular targeted drugs and immunotherapy, the survival …

15 - 59 years of age All Phase 2
M Min Shi, MD & Ph. D

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

This is a Single-arm, Open-label, Phase 1b/2 Study of IBI343 Combined with Sintilimab Plus Chemotherapy in Previously Untreated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

18 - 75 years of age All Phase 1/2
Z Zhijun Dai, Professor

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response(PCR) of Adjuvant treatment of TNBC breast cancer with Toripalimab combined with neoadjuvant chemotherapy, including the incidences and types of adverse events. The secondary study objective is to …

18 - 70 years of age Female Phase 2
Y Yu Wang, M.D.

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

This study aims to investigate the efficacy and safety of combining sintilimab and the TP regimen with/without IBI110 for neoadjuvant chemotherapy in resectable locally advanced head and neck squamous cell carcinoma (HNSCC).

18 - 75 years of age All Phase 1/2
J Junling Li, Doctor

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.

18 years of age All Phase N/A
C Chaoqun Fei, M.D.

Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma

Dear Sir/Madam, We would like to invite you to participate in this clinical research, which has been approved by the Medical Ethics Committee of Zhejiang Cancer Hospital. This informed consent form provides you with detailed information to help you decide whether or not to participate in this study. Please read …

18 - 75 years of age All Phase 1/2
Y Yuanming Shen, Dr

Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with recurrent ovarian cancer after PARPi maintenance, and to clarify whether patients with recurrent ovarian cancer after PARPi maintenance for more …

18 - 70 years of age Female Phase N/A
H Hong-Xu Liu, M.D.

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.

18 - 75 years of age All Phase 2

Simplify language using AI